M D Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA.
Leuk Lymphoma. 2011 Feb;52 Suppl 1(Suppl 1):81-91. doi: 10.3109/10428194.2010.546917.
Although imatinib revolutionized the management of chronic myeloid leukemia (CML), recent data indicate a transformation in the treatment approach likely in the near future. The superiority of second-generation tyrosine kinase inhibitors (TKIs) over imatinib in newly diagnosed disease has been recognized. Several investigational agents specific for those patients with the T315I mutation remain under evaluation. In Philadelphia-positive (Ph-positive) acute lymphoblastic leukemia (ALL), the addition of imatinib improved response rates. However, short remission durations with single agent therapy limit the benefit on survival. Early molecular remissions achieved with dasatinib will enable more patients to proceed to stem cell transplant (SCT), with increased likelihood of positive outcomes post-SCT.
虽然伊马替尼彻底改变了慢性髓性白血病（CML）的治疗方法，但最近的数据表明，这种治疗方法可能在不久的将来会发生转变。第二代酪氨酸激酶抑制剂（TKI）在新诊断疾病中的优越性已得到认可。几种针对 T315I 突变患者的研究药物仍在评估中。在费城染色体阳性（Ph 阳性）急性淋巴细胞白血病（ALL）中，加入伊马替尼可提高缓解率。然而，单一药物治疗的缓解时间较短，限制了对生存的益处。达沙替尼早期获得的分子缓解将使更多的患者能够进行干细胞移植（SCT），并且 SCT 后获得阳性结果的可能性增加。
